Francisella tularensis, the causative agent of tularemia, is in the top category (category A) of potential agents of bioterrorism. The F. tularensis live vaccine strain (LVS) is the only vaccine currently available to protect against tularemia; however, this unlicensed vaccine is relatively toxic and provides incomplete protection against aerosolized F. tularensis, the most dangerous mode of transmission. Hence, a safer and more potent vaccine is needed. As a first step toward addressing this need, we have constructed and characterized an attenuated version of LVS, LVS ⌬capB, both as a safer vaccine and as a vector for the expression of recombinant F. tularensis proteins. LVS ⌬capB, with a targeted deletion in a putative capsule synthesis gene (capB), is antibiotic resistance marker free. LVS ⌬capB retains the immunoprotective O antigen, is serum resistant, and is outgrown by parental LVS in human macrophage-like THP-1 cells in a competition assay. LVS ⌬capB is significantly attenuated in mice; the 50% lethal dose (LD 50 ) intranasally (i.n.) is >10,000-fold that of LVS. Providing CapB in trans to LVS ⌬capB partially restores its virulence in mice. Mice immunized with LVS ⌬capB i.n. or intradermally (i.d.) developed humoral and cellular immune responses comparable to those of mice immunized with LVS, and when challenged 4 or 8 weeks later with a lethal dose of LVS i.n., they were 100% protected from illness and death and had significantly lower levels (3 to 5 logs) of LVS in the lung, liver, and spleen than sham-immunized mice. Most importantly, mice immunized with LVS ⌬capB i.n. or i.d. and then challenged 6 weeks later by aerosol with 10؋ the LD 50 of the highly virulent type A F. tularensis strain SchuS4 were significantly protected (100% survival after i.n. immunization). These results show that LVS ⌬capB is significantly safer than LVS and yet provides potent protective immunity against virulent F. tularensis SchuS4 challenge.
Francisella tularensis is a Gram-negative coccobacillus that causes tularemia, a zoonotic disease spread among small animals such as rabbits and rodents by blood-sucking insects. Humans typically acquire tularemia by handling infected animals or from the bite of infected insects. There are four subspecies of F. tularensis: F. tularensis subsp. tularensis, holarctica, mediasiatica, and novicida (41) ; of these, F. tularensis subsp. tularensis, found in North America and also known as type A, causes the most severe disease. Following cutaneous exposure, tularemia typically presents as an ulceronodular disease with painful, ulcerated skin lesions and swollen lymph nodes. Following inhalation exposure, tularemia presents with acute flulike symptoms followed by pleuropneumonic and typhoidal illness. The pneumonic form of tularemia has a high fatality rate (11) .
Because of its high pathogenicity in humans, especially after respiratory exposure, its low infectious dose, and the relative ease with which it can be cultured and disseminated, F. tularensis is classified as a category A agent of bioterrorism, i.e., among bioterrorist agents thought to pose the greatest risk to the public. Indeed, F. tularensis was previously developed as a bioweapon and stockpiled by Japan during World War II (16) and by the United States and the Soviet Union during the Cold War (1, 6) . Although tularemia can be treated with available antibiotics, F. tularensis can be genetically engineered to be antibiotic resistant (30) . Moreover, pneumonic tularemia frequently requires hospitalization and intensive care, and even when an infected individual is treated with antibiotics to which the organism is sensitive, the disease may resolve slowly (12) ; even a moderately sized outbreak could rapidly overwhelm medical facilities (11) . Hence, relying on antibiotics to protect against a bioterrorist attack with F. tularensis is not a practical public health approach. A safe and potent vaccine, on the other hand, would appear to offer a much more reliable approach. An unlicensed vaccine known as the live vaccine strain (LVS), an attenuated mutant of F. tularensis subsp. holarctica, was developed in the mid-1900s and is the only vaccine currently available in the United States. The underlying mecha-nism of attenuation is not fully characterized genetically, although recently, the reintroduction of deleted genes pilA and FTT0918 was shown to restore virulence to the level of virulent type B strains (35) . The LVS vaccine has several drawbacks. The vaccine, which retains considerable virulence in animals, shows significant toxicity in humans after both intradermal (i.d.) and aerosol administration (19, 37) . Moreover, it provides incomplete protection to humans challenged with type A F. tularensis by aerosol, the route of transmission of greatest concern in a bioterrorist attack (19, 29, 37) .
In a search for a vaccine that is safer and more potent than LVS, we sought to rationally attenuate LVS and to use the attenuated LVS as both a vaccine and a vector to overexpress immunogenic F. tularensis proteins. We hypothesized that we would render LVS safer by further attenuating it and that we would render it more potent by overexpressing key immunoprotective antigens. This overall strategy mirrors that used successfully to develop the first vaccine against tuberculosis that is more potent than the current Mycobacterium bovis BCG vaccine, rBCG30, a recombinant BCG vaccine overexpressing the Mycobacterium tuberculosis 30-kDa major secretory protein, and to develop the first vaccine both safer and more potent than BCG, rBCG(mbtB) 30 , an attenuated version of rBCG30 that is engineered and propagated such that it can multiply only a few times in the host (20, 21, 45) .
In attenuating LVS, we sought a mutation that would greatly reduce virulence but have a minimal impact on immunogenicity and protective efficacy. Transposon mutagenesis studies of F. tularensis subsp. novicida and holarctica (LVS) have shown that mutants with transposon insertions in genes (FTT0806, FTT0805, and FTT0798) encoding proteins putatively involved in capsular biosynthesis, on the basis of partial amino acid sequence homology with capsular biosynthesis proteins of Bacillus anthracis, are highly attenuated (ϳ100-to 1,000-fold) in mice (43, 47) . Consequently, we decided to evaluate the vaccine potential of an LVS mutant with a deletion in one of these genes.
In this study, we describe the construction of an antibiotic resistance marker-free FTL_1416/FTT0805 (capB) deletion mutant of F. tularensis LVS (LVS ⌬capB) and show that LVS ⌬capB is resistant to serum killing, outgrown by its parental LVS in human macrophage-like THP-1 cells, and highly attenuated in mice. We demonstrate further that this vaccine, after both i.d. and intranasal (i.n.) administration, induces potent cellular and humoral immune responses and significant protective immunity against respiratory challenge with virulent F. tularensis.
MATERIALS AND METHODS
Cell lines, bacteria, and mice. Human macrophage-like THP-1 cells (ATCC TIB-202) were cultured in RPMI 1640 medium containing penicillin (100 g/ml) and streptomycin (100 U/ml) and supplemented with 10% fetal bovine serum (FBS). F. tularensis LVS and SchuS4 were obtained from the Centers for Disease Control and Prevention (Atlanta, GA). To prepare stocks, we passaged the bacteria once on phorbol-12-myristate-13-acetate (PMA)-differentiated monolayers of THP-1 cells, cultured them on chocolate II agar plates (BD BBL, Sparks, MD) for 3 days, scraped the colonies into sterile saline, resuspended the bacteria in the presence of 20% glycerol, and stored them frozen at Ϫ80°C. Before each use in animals, one vial of LVS or SchuS4 was removed from the freezer, immediately thawed in a 37°C water bath, diluted in sterile saline, and kept on ice until use.
Six-to eight-week-old specific-pathogen-free female BALB/c mice were pur-chased from Charles River Laboratory (Wilmington, MA) and used according to protocols approved by the animal research committees of the University of California-Los Angeles (UCLA) and Colorado State University (CSU).
Construction of an LVS mutant deficient in a putative capsule synthesis gene.
An antibiotic-marker-free LVS mutant with a deletion in a putative capsule biosynthesis gene, capB (FTL_1416/FTT0805), LVS ⌬capB, was constructed by allelic exchange. Briefly, approximately 1-kb upstream and downstream DNA fragments flanking the capB coding sequence were amplified from the genomic DNA of F. tularensis LVS. The two PCR fragments were ligated via an EcoRI site to form an in-frame capB deletion cassette. This cassette was cloned into suicide plasmid pMP590 (27) , bearing a kanamycin resistance gene and a sacB gene, and subsequently delivered into LVS by electroporation. LVS transformants were subjected to selection on chocolate agar made from GC medium base (BD Difco, Sparks, MD) supplemented with 1% hemoglobin in the presence of 10 g/ml kanamycin and subsequently on chocolate agar supplemented with 5% sucrose. The resulting LVS ⌬capB mutant does not carry any antibiotic resistance gene. To confirm the deletion of capB from the LVS ⌬capB chromosome, we amplified the mutated capB region by PCR using Phusion high-fidelity DNA polymerase (Finnzyme, Inc., Woburn, MA) and primer pair 5Ј-CGTAAA AAGGCGTTGGTGAT-3Ј and 5Ј-AGTCCTATCGAAGCCATATTAC-3Ј. We determined the nucleotide sequences of the amplified mutated capB region and its upstream 218-bp and downstream 370-bp regions and found them to be identical to the corresponding sequences of the LVS genome (www.francisella .org) but with an in-frame deletion of capB as expected.
A lipopolysaccharide (LPS)-deficient LVS mutant (LVS ⌬wbtDEF) was constructed and confirmed by genomic nucleotide sequencing of the mutated locus, using a strategy similar to those described above.
Southern blot analysis of bacterial genomic DNA. LVS and LVS ⌬capB were grown on chocolate agar at 37°C for 2 days. The genomic DNA was isolated by using a genomic DNA isolation kit according to the manufacturer's protocol (Qiagen, Valencia, CA). Bacterial genomic DNAs were subjected to EcoRV, HindIII, or AvaII digestion and separated on a 0.7% agarose gel. The gel was subjected to denaturation in alkaline fixation/transfer buffer (0.4 M NaOH, 1 M NaCl). The denatured DNA in the treated gel was transferred onto a charged nylon membrane (GE Healthcare, Pittsburgh, PA) by capillary transfer and hybridized with biotin-labeled probes at 55°C using the North2South chemiluminescent hybridization and detection kit (Pierce Biotechnology, Rockford, IL). Probes were generated by a North2South biotin random prime labeling kit (Pierce Biotechnology) according to the manufacturer's protocol, using a 1-kb Plus DNA ladder (Invitrogen) and an LVS genomic DNA fragment as templates. The DNA fragment for the probe was amplified from LVS genomic DNA by using primer pair 5Ј-AGGCGTCGACTGGTGATATCTATTATTATGATG-3Ј and 5Ј-AGAGCGGCCGCTAATACCTAAGATATCATAA-3Ј (restriction enzyme sites are underlined). Chemiluminescence signals were detected with a Chemi Doc XRS imaging system (Bio-Rad, Hercules, CA).
Quantitative RT-PCR. Colonies of F. tularensis grown on chocolate agar for 2 days were scraped into Chamberlain defined medium (5) , the bacterial suspension was adjusted to an initial optical density at 540 nm (OD 540 ) of 0.05, and the bacteria were subcultured aerobically to the mid-logarithmic growth phase (OD 540 of 0.6). Total RNA from approximately 6 ϫ 10 8 bacteria of each strain was extracted by using a RiboPure-Bacteria RNA isolation kit (Applied Biosystems/Ambion, Austin, TX) and subsequently treated with DNase according to the manufacturer's guidelines. The primers used for the quantitative PCR (qPCR) assays were designed by using Primer3 software (34) . Quantitative reverse transcription (RT)-PCR assays were performed in a two-step reaction. First, cDNA was synthesized by using a high-capacity cDNA reverse transcription kit (Applied Biosystems, Carlsbad, CA) with an iCycler instrument (Bio-Rad) under the following conditions: 25°C for 10 min, 37°C for 120 min, and 85°C for 5 s. For each 20-l reaction mixture, 2 l 10ϫ RT buffer, 0.8 l 100 mM deoxynucleoside triphosphate (dNTP) mix, 2.0 l random primers, 1.0 l Mul-tiScribe reverse transcriptase, 1.0 l of RNase inhibitor, 3.2 l of nuclease-free water, and 10 l of RNA template were added. After cDNA synthesis, qPCR assays were performed by using an ABI 7900 sequence detection system (Applied Biosystems). For each 25-l qPCR mixture, 12.5 l 2ϫ Power SYBR green PCR master mix (Applied Biosystems), 300 nM each primer pair, and 2 l of cDNA were added. Primer pairs used were 5Ј-CGGGTCATACCCAGCTTTAG-3Ј and 5Ј-GCTCCTGGAGTCATCCCATA-3Ј for capA, 5Ј-TCGAGTGTATGGCTTT GCAG-3Ј and 5Ј-AGCCTCGGTCTTTACAAGCA-3Ј for capB, 5Ј-ATGGGG GCTCCTGATAGAGT-3Ј and 5Ј-CCAATTACCTGAACTTGGTTTGA-3Ј for capC, 5Ј-CGTAAAAAGGCGTTGGTGAT-3Ј and 5Ј-ATAAAGCCACGACG ATTTGG-3Ј for FTL_1417, and 5Ј-CTGTCGTCAGCTCGTGTTGT-3Ј and 5Ј-CGTAAGGGCCATGATGACTT-3Ј for FTL_R0003 (16S rRNA). The amplification of cDNA with each pair of primers was performed under the following conditions: 1 cycle at 95°C for 10 min and 40 cycles at 95°C for 15 s and 60°C for 1 min. The 16S rRNA gene was used as an internal control.
Data collection was performed by using ABI Sequence Detection 1.3 software (Applied Biosystems). The expression levels of the target genes (capA, capB, capC, and FTL_1417) were normalized to levels of 16S rRNA and compared with LVS (baseline) by using the 2 Ϫ⌬⌬CT method (Applied Biosystems User Bulletin no. 2 [pN4303859]) for the relative quantitation of gene expression. Real-time data are presented as the fold change compared with LVS levels at the mid-logarithmic growth phase. Error bars represent the standard deviations of the ⌬⌬C T values. Statistical significance was determined by the Student t test.
Complement sensitivity assay. LVS ⌬capB and the parental LVS were grown on chocolate agar overnight, suspended in RPMI medium, incubated with either 10% fresh normal human serum (type AB) or heat-inactivated human serum at 37°C for 10 min, serially diluted, and plated onto chocolate agar plates.
Competition assay for growth in human macrophage-like THP-1 cells. To monitor the intramacrophage growth of an individual bacterial strain in a competitive assay, we introduced a pair of plasmids, pMP607 and pMP633, which harbor the aphA-1 gene and the hyg gene, respectively (27) , into the parental LVS and the capB deletion strain. This resulted in an LVS strain carrying a kanamycin resistance gene (LVS-kan) or a hygromycin resistance gene (LVShyg) and a comparable pair of LVS ⌬capB strains, each carrying one of the same antibiotic resistance genes (LVS ⌬capB-kan and LVS ⌬capB-hyg). Bacteria were grown on chocolate agar for 2 days, scraped into RPMI medium, and opsonized with 10% human serum (type AB). Human monocytic THP-1 cells were differentiated by treatment with 100 nM PMA for 3 days at a density of 3 ϫ 10 5 cells/ml. Bacteria were added to the differentiated THP-1 cells at a multiplicity of infection (MOI) of 10:1 (bacteria to cells), and the cultures were centrifuged at 1,000 ϫ g at 4°C for 30 min and subsequently incubated at 37°C for 60 min to allow bacterial uptake. Human macrophage-like THP-1 cells coinfected with LVS ⌬capB-hyg and LVS-kan or coinfected with the same two strains carrying the opposite resistance markers (LVS ⌬capB-kan and LVS-hyg) were washed three times to remove extracellular bacteria and cultivated in Dulbecco's modified Eagle's medium (DMEM) containing 10% heat-inactivated FBS and 0.1 g/ml gentamicin, a culture condition that we have determined suppresses extracellular bacterial growth but has a minimal impact on the growth of the intracellular bacteria. At various times postinfection, monolayers were scraped into homogenization buffer containing 250 mM sucrose and 20 mM HEPES (pH 7.2) and lysed with glass beads by vortexing 10 times in 2-s pulses. The lysates were serially diluted and plated onto chocolate agar containing 10 g/ml kanamycin or 250 g/ml hygromycin as appropriate. CFU were enumerated, and the ratio between the numbers of LVS ⌬capB CFU and LVS CFU was calculated at each time point.
Analysis of bacterial LPS and protein expression by Coomassie blue staining and Western blotting. Bacterial lysates were separated by 15% SDS-PAGE and transblotted onto nitrocellulose membranes. The membrane was incubated with a monoclonal antibody specific to F. tularensis LPS (FB11; Abcam, Inc., MA) at a dilution of 1:5,000 and subsequently with horseradish peroxidase-conjugated goat anti-mouse immunoglobulin G (Bio-Rad, Hercules, CA) at a dilution of 1:25,000. Signals on the blot were developed by using the Supersignal West Pico chemiluminescent substrate (Pierce, Rockford, IL). Proteins in the bacterial lysates were visualized by Coomassie blue staining as a control for equal loading.
Complementation of truncated capB. The DNA fragment encoding wild-type capB was PCR amplified from LVS genomic DNA by using Phusion high-fidelity DNA polymerase (Finnzyme) and primer pair 5Ј-CTCATATGTTGGATTTTT GGTTAATTGT-3Ј and 5Ј-ACAGGATCCCTATAAATTATGCTTCTTTT-3Ј (the restriction enzyme sites are underlined). The PCR product was cloned into pZErO (Invitrogen, Carlsbad, CA) and verified by nucleotide sequencing. The confirmed capB coding sequence was subcloned into the NdeI and BamHI sites downstream of the groE promoter in the shuttle vector pFNLTP6/gro-gfp (28) , in which the gfp coding sequence was replaced by the capB coding sequence. The resultant plasmid, pFNLTP/gro-capB, was electroporated into LVS ⌬capB. Transformants were selected on chocolate agar supplemented with 7.5 g/ml kanamycin and verified by colony PCR using a primer pair specific to the vector: 5Ј-GTATTAGTTCGTCGTGC-3Ј and 5Ј-GAGCCATCTTTATTGCG-3Ј. One of the verified clones, LVS ⌬capB/CapB, was amplified on chocolate agar supplemented with 7.5 g/ml kanamycin and used for further characterization studies.
Vaccination and challenge of mice. Vaccination and challenge of mice were conducted as described previously (23) . Briefly, mice were vaccinated by the i.d. or intranasal (i.n.) route. For i.d. vaccination, mice were shaved, decontaminated with 70% ethanol at the base of the tail, and injected by using 27-gauge needles and 1/2-ml tuberculin syringes (Becton Dickinson, NJ) with 50 l sterile phosphate-buffered saline (PBS) (negative control) or with various doses of LVS (positive control) or LVS ⌬capB diluted in 50 l PBS. For i.n. vaccination, mice were anesthetized by intraperitoneal (i.p.) injection with ketamine (80 mg/kg of body weight) and xylazine (10 mg/kg), and vaccines serially diluted in sterile PBS were administered into the nostrils in a total volume of 20 l. At various times after vaccination, mice were either euthanized for immunology studies or challenged by the i.n. route at UCLA with 4,000 CFU LVS (Ͼ5ϫ the 50% lethal dose [LD 50 ]), administered in the same way for i.n. vaccination, or by the aerosol route at CSU with 10ϫ the LD 50 of type A F. tularensis strain SchuS4. The aerosol challenge was conducted in a chamber of 5 cubic feet with the mice conscious and active, using a Glas-Col inhalation exposure system (Glas-Col LLC, Terre Haute, IN). The dose of 10ϫ the LD 50 for strain SchuS4 was obtained by aerosolizing 5 ml of a suspension containing 3.2 ϫ 10 7 to 3.4 ϫ 10 7 CFU/ml of bacteria over a period of 15 min. The actual number of bacteria in the nebulizer was confirmed by culturing the bacterial suspension in duplicate on chocolate agar. Challenged mice were weighed and monitored for illness and death for 3 weeks. Mice that met predetermined humane endpoints for euthanasia were euthanized and counted as a death. The mean survival time was calculated by dividing the sum of the surviving days of all mice by the total number of mice examined, with animals surviving until the end of the experiment given a survival time of 21 days, when the experiment was terminated.
To quantitate bacterial burden in host tissues, mice were euthanized at 5 days postinfection. Liver, spleen, lung, and, in the case of i.d. immunization, a 1-cm 2 area of local skin at the injection site were removed aseptically and immediately weighed, immersed in 2 ml sterile PBS, and kept on ice until homogenization. The homogenization was performed by using a Pro200 homogenizer (Pro Scientific, Inc., Oxford, CT). Serial 10-fold dilutions of the homogenates were plated onto cysteine heart agar supplemented with 1% (wt/vol) hemoglobin and sulfamethoxazole (40 g/ml), trimethoprim (8 g/ml), and erythromycin (50 g/ml) (24) and incubated in a 5% CO 2 atmosphere at 37°C for 3 days before colonies were enumerated (23) . The supplementation of sulfamethoxazole, trimethoprim, and erythromycin in the agar was done to prevent contamination from the mouse tissues. We have determined that the doses of these three antibiotics used in our experiments have a minimal inhibitory effect on the growth of LVS.
Assay for lymphocyte proliferation. Groups of four BALB/c mice were sham immunized or immunized i.d. with 1 ϫ 10 5 CFU LVS or 1 ϫ 10 6 CFU LVS ⌬capB or immunized i.n. with 112 CFU LVS or 1 ϫ 10 5 CFU LVS ⌬capB. At 4 weeks postimmunization, mice were anesthetized by the i.p. injection of ketamine and xylazine, bled, and then euthanized. Sera were collected for serum antibody measurements as described below. Spleens were removed, and a singlecell suspension of splenocytes was prepared. Lymphocyte proliferation in response to heat-inactivated LVS antigen was assayed as described previously, with modifications (23). Splenocytes from each animal were cultured in triplicate and stimulated with heat-inactivated LVS for 48 h. Two hours before harvesting, the stimulated splenocytes were pulsed with [methyl-3 H]thymidine and harvested with a Combi cell harvester (Molecular Devices/Skatron, Sunnyvale, CA). The amount of incorporated [ 3 H]thymidine was determined by counting with an LS 6500 scintillation system (Beckman Coulter, Fullerton, CA) and the values were expressed as counts per minute (cpm).
Heat-inactivated LVS antigen was prepared by growing LVS on chocolate agar for 2 days, scraping the bacteria into PBS, and incubation at 80°C for 1 h. The loss of viability was confirmed by plating the antigen onto chocolate agar and incubation at 37°C for 2 days. No colonies were detected on the plates, indicating that no viable bacteria survived heat inactivation.
Serum antibody detection by enzyme-linked immunosorbent assay (ELISA). Sera collected from sham-immunized mice or mice immunized with LVS or LVS ⌬capB were analyzed for levels of IgM, IgA, IgG, IgG1, and IgG2a antibodies specific for LVS as described previously (23) . The heat-inactivated LVS antigen was diluted in carbonate-bicarbonate buffer (50 mM NaHCO 3 , 50 mM Na 2 CO 3 ) to an optical density of 0.025 at 540 nm (equivalent to 5 ϫ 10 6 CFU/0.1 ml), and 0.1 ml was used to coat 96-well high-binding-capacity plates (Corning, NY) for 2 h at 37°C. Excess antigen was removed by washing three times with PBS. Sera at a starting dilution of 1:32 were diluted further through a 2-fold series with PBS containing 1% bovine serum albumin. The diluted sera were incubated with heat-inactivated LVS coated onto 96-well plates at an ambient temperature for 3 h. The plates were subsequently incubated for 90 min at an ambient temperature with alkaline phosphatase-conjugated goat anti-mouse IgA (Sigma, St. Louis, MO), IgM, IgG1, or IgG2a (Invitrogen) at a dilution of 1:1,000. The plates were washed three times with PBS containing 0.05% Tween 20 after each incubation. One hundred microliters of p-nitrophenyl phosphate substrate in diethanolamine buffer (phosphatase substrate kit; Bio-Rad, Hercules, CA) was added to each well. The yellow color that developed was read at 414 nm for absorbance by using a Multiscan microplate reader (TiterTek, Huntsville, AL antibody titer was calculated as the reciprocal of the highest serum dilution that was a minimum of 0.05 optical density units above that of the sham-immunized control serum plus 2 standard errors (SE). Statistical analysis. One-way analysis of variance (ANOVA) with Tukey's posttest or two-way ANOVA with Bonferroni's posttest was performed by using GraphPad (San Diego, CA) Prism software, version 5.01, to determine significance in comparisons of mean CPMs for lymphocyte proliferative responses, mean antibody titers, and mean log 10 CFU organ counts among mice in vaccinated and control groups. A log-rank analysis (Mantel-Cox test) using GraphPad Prism, version 5.01, was used to determine the significance of survival curves among mice in immunized and in sham-immunized control groups.
RESULTS
Construction and in vitro characterization of LVS ⌬capB, an LVS mutant deficient in a putative capsule synthesis gene. We used allelic exchange to construct a putative capsule-deficient mutant (LVS ⌬capB) in which the capB gene (FTL_1416/ FTT0805) was partially deleted without interrupting its neighboring genes. The resultant LVS ⌬capB mutant is free of an antibiotic resistance marker, and the truncated capB contains 30 nucleotides encoding 6 amino acids from the N terminus and 4 amino acids from the C terminus of CapB ( Fig. 1A) , as confirmed by nucleotide sequencing of the mutated genomic region. To confirm further the genomic structure of the capB locus, we performed Southern blotting on the genomic DNA of LVS ⌬capB and the parental LVS isolated from bacteria grown on chocolate agar for 2 days. The genomic DNA was treated with EcoRV, HindIII, or AvaII; separated by electrophoresis on a 0.7% agarose gel; blotted; and probed with a biotinlabeled 3.4-kb genomic DNA fragment spanning capB, most of the upstream region of FTL_1417, the entire downstream region of capC, and most of the further downstream region of capA. As shown at the top of Fig. 1B for LVS, the probe is predicted to hybridize with two DNA fragments of 1.6 and 1.7 kb in EcoRV digests; six fragments of 5.8, 0.8, 0.5, 1.0, 0.3, and 1.5 kb in HindIII digests; and three fragments of 1.6, 1.2, and 3.1 kb in AvaII digests. As shown at the bottom of Fig. 1B for LVS ⌬capB, due to the loss of capB, the same probe is predicted to hybridize with one fragment of 2.2 kb in EcoRV digests; four fragments of 5.8, 1.1, 0.3, and 1.5 kb in HindIII digests; and two fragments of 1.7 and 3.1 kb in AvaII digests. As shown in Fig. 1C , the probe detected each of the predicted DNA fragments in EcoRV-, HindIII-, or AvaII-treated genomic DNA of LVS and LVS ⌬capB. These results further confirmed that capB was deleted from the LVS ⌬capB genome and that there were no additional DNA rearrangements in the chromosomal region where capB resides.
To determine whether the deletion of capB affects the transcription of its upstream and downstream genes, we isolated total RNA of LVS ⌬capB, the parental LVS, and capB-complemented LVS ⌬capB (LVS ⌬capB/CapB) from mid-logarithmic-phase cultures in Chamberlain defined medium and treated them with DNase to eliminate possible genomic DNA contamination. We then analyzed the transcript levels of FTL_1417, capB, capC, capA, and the 16S rRNA gene (serving as an internal control) in all three strains by using a two-step qPCR assay. We compared the fold changes of these transcripts between LVS ⌬capB and LVS and between LVS ⌬capB/CapB and LVS. As shown in Fig. 1D , we found that (i) the transcript of capB was not detectable in LVS ⌬capB; (ii) the transcript level of capB in LVS ⌬capB/CapB was signifi-cantly (ϳ16-fold) higher than that in LVS, indicating that multiple copies of pFNLTP/gro-capB likely reside in LVS ⌬capB/CapB; and (iii) there were no significant changes in the transcript levels of capA and capC between LVS ⌬capB and LVS or between LVS ⌬capB/CapB and LVS. In addition, we verified that there was no genomic DNA contamination in each of the RNA samples, since in the absence of reverse transcription, no PCR product was generated in each of the samples (Fig. 1E ). These results demonstrate that the deletion of capB minimally affected the transcript levels of its upstream and downstream genes FTL_1417, capC, and capA.
To determine whether LVS ⌬capB produces LPS, we analyzed bacterial lysates of LVS and LVS ⌬capB by Coomassie blue staining and Western blotting. We observed similar profiles of protein expression ( Fig. 2A, right) and similar ladderlike patterns of LPS immunoreactivity ( Fig. 2A, left) for LVS and LVS ⌬capB. To assess serum sensitivity, we incubated the mutant and the parental LVS in fresh human serum. We observed that LVS ⌬capB, like the parental LVS, is not sensitive to serum-mediated killing (Fig. 2B ). In contrast, an LPS-deficient LVS mutant (LVS ⌬wbtDEF) was readily killed by complement in human serum ( Fig. 2B) .
To evaluate the attenuation of LVS ⌬capB in vitro, we compared the intramacrophage growth of LVS ⌬capB with that of LVS in human macrophage-like THP-1 cells in a growth competition assay. We found that the LVS ⌬capB mutant carrying either a hygromycin or kanamycin resistance marker grew more slowly than the parental LVS carrying the opposite antibiotic resistance marker (kanamycin or hygromycin, respectively) (Fig. 2C ). This result indicated that the LVS ⌬capB mutant is more attenuated than the parental LVS in human macrophage-like THP-1 cells.
LVS ⌬capB is more attenuated than parental LVS in mice. To compare the virulence of LVS ⌬capB with that of the parental LVS in vivo ( Fig. 3A1 and A2), we immunized BALB/c mice (four mice per group) with LVS ⌬capB at doses ranging from 1 ϫ 10 6 to 1 ϫ 10 8 CFU i.d. or from 1 ϫ 10 3 to 1 ϫ 10 7 CFU i.n. Mice immunized with LVS at doses ranging from 1 ϫ 10 5 to 1 ϫ 10 7 CFU i.d. or 1.5 ϫ 10 2 to 4.1 ϫ 10 3 CFU i.n. and nonimmunized mice served as controls. The mice were weighed daily from day 2 postchallenge and observed for signs of illness, death, and, for mice immunized i.d., the extent of a local lesion for 3 weeks. As shown in Fig. 3A1 , for mice administered LVS i.d., 100% of mice survived after immunization at the doses tested in this experiment. However, mice immunized i.d. with 1 ϫ 10 7 CFU LVS developed severe local lesions. In an experiment performed separately, we immunized BALB/c mice (nine mice per group) i.d. with 1 ϫ 10 4 to 1 ϫ 10 8 CFU LVS/mouse and monitored for 2 weeks. One hundred percent of mice survived after i.d. immunization with 1 ϫ 10 4 to 1 ϫ 10 7 CFU LVS, consistent with the results shown in Fig.  3A1 . However, all nine mice immunized with 1 ϫ10 8 CFU of LVS died on days 4 to 6 postimmunization, with a mean survival time of 4.25 days. In contrast, for mice administered LVS ⌬capB i.d., 100% of the mice survived doses of 10 6 to 10 8 CFU (versus 0% survival at a dose of 10 8 CFU for LVS). Although mice immunized with 10 8 CFU LVS ⌬capB i.d. had early weight loss, these mice had no other signs of illness and showed only mild local inflammation at the injection site ( Fig. 3A1 ).
For mice administered LVS i.n., deaths occurred and at relatively low doses such that the LD 50 i.n. was ϳ700 CFU (versus Ͼ10 7 CFU for LVS ⌬capB). All mice immunized i.n.
with LVS at each dose tested showed signs of illness (ruffled fur and hunched back), and they had significant weight loss between days 4 and 9 after immunization (Fig. 3A2 ). In contrast, for mice immunized i.n. with LVS ⌬capB, 100% of mice survived after immunization at all tested doses, and only transient weight loss occurred between day 2 and day 6 postimmunization, at doses of 1 ϫ 10 6 CFU and 1 ϫ 10 7 CFU/mouse (Fig. 3A2 ).
To evaluate further the safety of LVS ⌬capB and to confirm that the attenuated phenotype of LVS ⌬capB was due to the loss of only capB, we constructed a capB-complemented strain, LVS ⌬capB/CapB, and compared its virulence with those of LVS ⌬capB and the parental LVS via the i.n. route, the route by which LVS is most virulent. BALB/c mice in groups of four were immunized with LVS (6.7 ϫ 10 1 to 6.7 ϫ 10 4 CFU), LVS ⌬capB (10 4 to 10 7 CFU), or LVS ⌬capB/CapB (10 4 to 10 7 CFU) ( Fig. 3B1 to B3 ). Mice were monitored and weighed for 2 weeks daily starting from the day of immunization (day 0). As shown in Fig. 3B1 to B3, mice immunized with LVS at each of the tested doses had significant weight loss and an LD 50 of approximately 700 CFU (Fig. 3B1) , and mice immunized with LVS ⌬capB had 100% survival at each of the tested doses, with transient weight loss in mice immunized with 10 6 or 10 7 CFU (Fig. 3B2) . In contrast to LVS ⌬capB-immunized mice, mice immunized with LVS ⌬capB/CapB at doses ranging from 10 5 to 10 7 CFU showed significant weight loss and death. Thus, the attenuated phenotype of LVS ⌬capB was partially restored by providing CapB in trans. Taken together with the results from genomic nucleotide sequencing, Southern blotting, the quantitative RT-PCR assay, and the in vivo virulence test, the attenuated phenotype of LVS ⌬capB was due to the loss of capB.
In subsequent experiments evaluating the immunogenicity and efficacy of the i.d. route of immunization, we generally used doses of 10 6 CFU of LVS ⌬capB and 10 5 CFU of LVS. At these doses, LVS ⌬capB was nontoxic in mice and caused no apparent inflammation at the site of injection. In contrast, LVS retained significant toxicity, e.g., causing ruffled fur. In subsequent experiments evaluating the i.n. route of immunization, we generally used doses of 10 5 CFU LVS ⌬capB and approximately 200 CFU LVS. Again, at these doses, LVS ⌬capB was completely nontoxic, whereas LVS retained significant toxicity, resulting in ruffled fur and a hunched back in immunized animals; moreover, in two experiments, even this low dose of LVS proved to be lethal to 25% of immunized animals.
These results demonstrated that LVS ⌬capB is at least 10,000-fold-more attenuated than LVS after i.n. immunization and substantially more attenuated after i.d. immunization.
LVS ⌬capB is cleared faster than LVS after intranasal infection. To assess the dissemination and clearance of LVS ⌬capB, we immunized groups of four BALB/c mice i.n. with 112 CFU LVS or 1 ϫ 10 5 CFU LVS ⌬capB or i.d. with 1 ϫ 10 5 CFU LVS or 1 ϫ 10 6 CFU LVS ⌬capB. At various times postimmunization, mice were euthanized, and spleen, liver, lung, and skin at the injection site (in the case of i.d. immunization) were assayed for bacterial burden. As shown in Fig. 4A , following i.n. immunization, LVS replication peaked at day 4 in the lung and at day 7 in the spleen and liver; the LVS was cleared by day 22 postimmunization in all three organs examined. In contrast, although the LVS ⌬capB mutant was administered at a much higher dose i.n. (10 5 CFU versus 112 CFU for LVS), LVS ⌬capB replicated at levels significantly lower than those of LVS at the peak of infection, and it was cleared faster than LVS in all three organs. Following i.d. immunization (Fig. 4B) , LVS ⌬capB replicated less efficiently in the local injection area than did the parental LVS. However, LVS ⌬capB spread systemically to the liver and spleen, where it was cleared at a rate similar to or greater than that of the parental LVS. The replication of both LVS ⌬capB and its parental LVS in the lung was limited (Fig. 4B) .
These results demonstrated that LVS ⌬capB is cleared much Each bacterial strain was incubated with either fresh human AB serum (ABS) or heat-inactivated AB serum (HI-ABS) for 10 min and then assayed for CFU on chocolate agar. This experiment was performed three times, with similar results. (C) Competition for growth in human macrophage-like THP-1 cells. THP-1 cells were coinfected with LVS ⌬capB carrying a hygromycin resistance gene (⌬capB-h) and with LVS carrying a kanamycin resistance gene (LVS-k) (solid circles, left vertical axis) or with the same two strains carrying the opposite resistance markers (solid squares, right vertical axis). At 0, 7, and 22 h postinfection, the cell monolayer was lysed, serial dilutions of the lysate were plated onto chocolate agar supplemented with either kanamycin or hygromycin, CFU were enumerated, and the ratio between the numbers of LVS ⌬capB and LVS CFU was calculated. The ratios of LVS ⌬capB to LVS CFU on the left and right vertical axes differ because of the variability among the four strains in the numbers of CFU recovered from THP-1 monolayers at the start of the experiment. For the competition data shown on the left axis, the initial number of LVS ⌬capB organisms was greater than the initial number of LVS organisms (initial ratio of ϳ10:1), and for the competition data shown on the right axis, the initial number of LVS ⌬capB organisms was fewer than the initial number of LVS organisms (initial ratio of ϳ0.4:1). In both cases, LVS ⌬capB was outcompeted by LVS, and therefore, the ratio of LVS ⌬capB CFU to LVS CFU declined with time in culture. This experiment was performed twice, with similar results. faster than LVS in mice after i.n. inoculation and at least as fast as LVS after i.d. inoculation.
Immunization with LVS ⌬capB induces strong cell-mediated and humoral immune responses. To examine whether immunization with LVS ⌬capB induces cell-mediated and humoral immune responses, we immunized groups of four mice with LVS ⌬capB at doses of 1 ϫ 10 5 CFU by the i.n. route or 1 ϫ 10 6 CFU by the i.d. route, doses that were nontoxic ( Fig.  3) and that provided excellent protection against i.n. LVS challenge (see below). At 4 weeks postimmunization, mice were anesthetized, bled, and euthanized (Fig. 5A) , and cellmediated and humoral immune responses were assayed as described in Materials and Methods. With respect to cellmediated immunity, immunization with LVS ⌬capB i.n. or i.d. induced LVS-specific splenic lymphocyte proliferative responses that were significantly higher than those of shamimmunized mice and comparable to those of LVS-immunized mice (Fig. 6 ). With respect to humoral immune responses ( Fig.  7) , following i.n. immunization, LVS ⌬capB induced significantly higher levels of IgG, IgG2a, and IgM antibodies than LVS by 7 days postimmunization ( Fig. 7A, C, and E) . At 14 days after immunization, mice immunized i.n. with LVS had a transiently significantly elevated IgA antibody level (Fig. 7D ). After 14 days postimmunization, there were no significant dif- ferences in IgG, IgG1, IgG2a, IgA, and IgM antibody levels between mice immunized with LVS and those immunized with LVS ⌬capB via the same route (i.e., either the i.n. or i.d. route) ( Fig. 7) . Interestingly, by 4 days after immunization, both LVS ⌬capB and LVS induced significantly elevated titers for IgG, IgG2a, and IgM by the i.d. route and IgM by the i.n. route compared with titers on day 1 postimmunization.
Thus, LVS ⌬capB, while highly attenuated, induces cellular and humoral immune responses comparable to those of LVS after i.n. or i.d. immunization.
Immunization with LVS ⌬capB protects mice from lethal intranasal challenge with LVS. To examine the capacity of LVS ⌬capB to induce protective immunity against lethal challenge with F. tularensis, we immunized mice i.n. or i.d with LVS ⌬capB at various doses (Fig. 5B and C and 8) . Sham-immunized mice and mice immunized with LVS (150 CFU i.n. and 1 ϫ 10 5 or 1 ϫ 10 6 CFU i.d.) served as controls. At 4 weeks postimmunization, mice were challenged i.n. with 4,000 CFU LVS (Ͼ5ϫ the LD 50 ). Five days after challenge, approximately the peak time of bacterial growth in the host with an LVS i.n. challenge dose of 4,000 CFU, mice were euthanized, and the liver, spleen, and lung were harvested and assayed for bacterial burden (Fig. 5B ). As shown in Fig. 8 , in mice immunized with LVS ⌬capB i.n. or i.d., the bacterial burden in the spleen, liver, and lung was significantly (3 to 4 logs) lower than that in sham-immunized animals. In the spleen of mice immunized i.n. with various doses of LVS ⌬capB or 150 CFU of the parental LVS, there were no significant differences in bacterial burdens between mice immunized i.n. with LVS and mice immunized with various doses of LVS ⌬capB, except for the dose of 10 3 CFU (P Ͻ 0.01) (Fig. 8A) . In the spleens of mice immunized i.d., there were no significant differences in F. tularensis LVS burden between mice immunized with 10 6 to 10 8 CFU of LVS ⌬capB and mice immunized with 10 5 to 10 6 CFU of LVS (Fig.  8B ). In the livers of mice immunized i.n. or i.d., there were no significant differences in bacterial burden between mice immunized with LVS ⌬capB and mice immunized with LVS ( Fig. 8C  and D) . In the lungs of mice immunized i.n., there were no significant differences in the bacterial burden between mice immunized with LVS and mice immunized with various doses of LVS ⌬capB, except for the dose of 10 3 CFU (P Ͻ 0.01) (Fig.  8E ). In the lungs of mice immunized i.d. with LVS ⌬capB and the parental LVS, although the bacterial burden in mice immunized with 10 6 or 10 7 CFU LVS ⌬capB was significantly higher (P Ͻ 0.01 and P Ͻ 0.05, respectively) than that in mice immunized with 10 5 CFU LVS, the bacterial burden in these LVS ⌬capB-immunized mice was comparable to that of mice immunized with 10 6 CFU LVS (Fig. 8F) .
Thus, the protection induced by immunization with LVS ⌬capB was dose dependent. Among all the doses of LVS ⌬capB tested, we found that doses of 1 ϫ 10 5 CFU i.n. and 1 ϫ 10 6 CFU i.d. were both well tolerated and induced protection in mice against F. tularensis challenge comparable to that of LVS. Therefore, in subsequent challenge experiments and the experiments described above in which immune responses were evaluated, we used these doses to immunize mice.
The above-described results indicated that in mice immunized with LVS ⌬capB and then challenged with F. tularensis LVS, both local replication in the lung and systemic dissemination of F. tularensis are strongly inhibited.
To determine further if immunization with LVS ⌬capB can provide protection against lethal LVS challenge in mice, we immunized groups of 12 mice once i.n. with approximately 200 CFU LVS (the maximum dose at which the majority of mice consistently survive) or 1 ϫ 10 5 CFU LVS ⌬capB or once i.d. with 1 ϫ 10 5 CFU LVS or 1 ϫ 10 6 CFU LVS ⌬capB (Fig. 9) . Notably, 25% (3/12) of mice immunized i.n. with just 200 CFU LVS died within 10 days of immunization, further underscoring the toxicity of LVS. In contrast, mice immunized with LVS ⌬capB i.n. or i.d. did not show any signs of illness. At 4 weeks postimmunization, surviving mice were challenged i.n. with 4,000 CFU LVS (Ͼ5ϫ the LD 50 ). Four of 12 mice in each group were euthanized at 5 days postchallenge, and lung, liver, and spleen were removed for assays of bacterial burden ( Fig.  5B and 9A) . The remaining eight mice in each group (except the LVS i.n. group, where only five mice remained) were monitored for signs of illness, weight loss, and death for 3 weeks (Fig. 5C and 9B) . Mice immunized i.n. or i.d. with LVS ⌬capB and challenged 4 weeks later had lung bacterial burdens Ͼ4 logs lower after i.n. immunization and 2 logs lower after i.d. immunization than those of sham-immunized mice; the num-ber of CFU in the spleen was below the limit of detection after i.n. immunization and was ϳ4 logs lower than that in shamimmunized mice, similar to mice immunized with LVS, and F. tularensis levels in the liver were below the limit of detection after both i.d. and i.n. immunization, similar to mice immunized with LVS ( Fig. 9A) . Importantly, the bacterial burden in mice immunized with LVS ⌬capB was 3 logs lower than that in mice immunized with the LPS deletion mutant LVS ⌬wbtDEF (data not shown). Although mice immunized with LVS ⌬capB had a somewhat higher bacterial burden in the lung than mice immunized with LVS, these mice showed no signs of illness after challenge. In the survival part of the study, 100% of mice immunized i.n. or i.d. with LVS ⌬capB and challenged with LVS i.n. at 4 weeks postimmunization survived, the same as what was found for mice immunized i.n. or i.d. with LVS ( Fig. 9C) .
To evaluate the protection provided by immunization with LVS ⌬capB after a longer immunization-challenge interval, we immunized groups of 12 mice i.n. or i.d. with LVS or LVS ⌬capB as described above and challenged them i.n. with 4,000 CFU LVS at 8 weeks postimmunization ( Fig. 9B and D) . Again, 25% (3/12) of mice immunized i.n. with LVS died within 10 days of immunization, consistent with the results described above. At 5 days postchallenge, mice immunized with LVS ⌬capB i.n. or i.d. had significantly lower bacterial burdens than sham-immunized mice in all three organs examined (Fig. 9B) . In mice immunized i.n., LVS-immunized animals had significantly fewer CFU in the spleen and lung than did LVS ⌬capB-immunized animals. In the liver, there was no significant difference in CFU between animals immunized with LVS and those immunized with LVS ⌬capB. In mice immunized i.d., there was no significant difference in CFU between LVS ⌬capBand LVS-immunized animals in any of the three organs assayed (Fig. 9B ). In the survival part of the study (Fig.  9D) , all eight sham-immunized animals died, whereas all animals immunized with LVS ⌬capB or LVS i.n. or i.d. survived Thus, LVS ⌬capB, while much less virulent than LVS, induces potent protective immunity against lethal LVS i.n. challenge, comparable to that induced by LVS.
Immunization with LVS ⌬capB protects mice from aerosol challenge with virulent F. tularensis strain SchuS4. To further define the protective immunity induced by immunization with LVS ⌬capB, we evaluated the capacity of the vaccine to protect against highly virulent F. tularensis strain SchuS4. We immunized groups of eight mice once i.n. with 1 ϫ 10 5 CFU LVS ⌬capB or i.d. with 1 ϫ 10 6 CFU LVS ⌬capB, challenged the mice 6 weeks later by aerosol with 10ϫ the LD 50 of F. tularensis SchuS4, and monitored the animals for weight change, signs of illness, and death for 3 weeks (Fig. 5D and 10) . Mice sham immunized with PBS or immunized with LVS (200 CFU i.n. or 1 ϫ 10 5 CFU i.d.) served as controls. Mice immunized with LVS ⌬capB developed strong protective immunity to F. tularensis SchuS4 challenge (Fig. 10) . In mice immunized i.d. (Fig.  10A and C) , protection was incomplete. All LVS ⌬capBand sham-immunized mice succumbed to challenge; however, LVS ⌬capB-immunized mice survived twice as long (10 days) as sham-immunized mice (5 days; P Ͻ 0.0001). LVS-immunized mice were better protected than LVS ⌬capB-immunized mice (62.5% versus 0% survival); however, all these mice showed substantial weight loss after challenge (Fig. 10A) .
In mice immunized with LVS ⌬capB i.n. (Fig. 10D) , 100% of the mice survived challenge, versus 0% for sham-immunized animals (P Ͻ 0.0001). Similarly, 100% of LVS-immunized animals survived. Notably, the LVS ⌬capBand LVS-immunized animals showed no signs of illness after challenge, e.g., no weight loss (Fig.  10B) .
Thus, LVS ⌬capB induces potent protective immunity against F. tularensis SchuS4 aerosol challenge, especially after i.n. immunization. Protection after i.n. immunization is stronger than that after i.d. immunization and comparable to that induced by LVS.
DISCUSSION
Our study shows that LVS ⌬capB is Ͼ10,000-fold-less virulent than LVS by the i.n. route. Importantly, after both i.n. and i.d. administration of completely nontoxic doses, doses Ͼ100- In rationally attenuating LVS for use as a vaccine and vector, the challenge was to construct a significantly less virulent mutant with little or no loss in immunogenicity and immunoprotective capacity. Indeed, our first choice for an attenuated vector failed in this respect. We initially constructed O-anti-gen-deficient mutants, one with a wbtDEF deletion (LVS ⌬wbtDEF) and the other with a wzy deletion (LVS ⌬wzy). Unfortunately, as a result of the loss of the O antigen, the LVS ⌬wbtDEF and LVS ⌬wzy mutants were highly sensitive to complement-mediated killing and, consequently, were overattenuated in mice such that they provided only limited protection to mice against i.n. challenge with F. tularensis LVS and no protection against aerosol challenge with virulent type A strain SchuS4. Hence, to avoid one mechanism of overattenuation, for our next choice of an attenuated LVS vector, LVS ⌬capB, we chose to delete a gene that would not render the mutant serum sensitive. As described in Results, LVS ⌬capB is highly resistant to human serum.
Whereas nontoxic but still highly immunogenic doses of LVS ⌬capB, e.g., 1 ϫ 10 5 CFU, could be administered readily by the i.n. route, it was difficult to deliver an immunogenic dose of LVS by the i.n. route that was consistently nonlethal let alone nontoxic; even the i.n. administration of 200 CFU, a dose that was moderately toxic in earlier experiments but initially appeared to be sufficiently below the LD 50 of 700 CFU so as to be nonlethal, resulted in 25% of mice dying in subsequent experiments.
By the i.d. route, both LVS ⌬capB and LVS were nonlethal at the immunizing doses used. However, whereas LVS ⌬capB at the immunizing dose of 10 6 CFU caused no toxicity, including none at the site of injection, LVS at the immunizing dose of 10 5 CFU was still mildly toxic, resulting in ruffled fur.
Because both the i.n. and i.d. doses of LVS used in efficacy experiments were still somewhat toxic, and in the case of the i.n. route sometimes even lethal, whereas both the i.n. and i.d. doses of LVS ⌬capB that were used were completely nontoxic, the efficacy studies were biased in favor of the LVS vaccine. Nevertheless, against lethal i.n. F. tularensis LVS challenge, LVS ⌬capB induced protective immunity comparable to that of LVS by both routes of administration (100% protection), and against aerosol challenge with F. tularensis SchuS4, LVS ⌬capB induced protective immunity comparable to that of LVS by the i.n. route (100% protection). The protective efficacy of LVS ⌬capB by the i.d. route was less than that induced by LVS, but protection was statistically significant; compared with sham-immunized animals, LVS ⌬capB-immunized animals survived twice as long after challenge.
The deletion of capB appears to confer just the right degree of attenuation upon the LVS ⌬capB mutant such that it is neither overattenuated, and hence unable to disseminate and induce a potent protective immune response, nor underattenuated and still too virulent. Consequently, at doses of LVS ⌬capB that were completely nontoxic, it was able to induce potent protective immunity against lethal respiratory challenge with F. tularensis.
The capB deletion clearly renders LVS ⌬capB highly attenuated, but exactly how it does so is unknown. The provisional designation of F. tularensis capB as a gene encoding an enzyme involved in capsule biosynthesis is based on the amino acid sequence homology of the F. tularensis CapB protein to a capsular biosynthetic protein of Bacillus anthracis. F. tularensis CapB is 37% identical to the B. anthracis capsule biosynthesis protein CapB (25) . Whether F. tularensis has a true capsule is unclear. A so-called capsule-deficient (Cap Ϫ ) mutant of F. tularensis and a chemically "decapsulated" F. tularensis strain have been reported to be avirulent in mice and guinea pigs (17, 36) . However, these organisms are serum sensitive, unlike the LVS ⌬capB mutant in our study, which is serum resistant. Also, unlike LVS ⌬capB, Cap Ϫ mutants are not genetically defined (17, 36, 42) , are unable to replicate in mice (17, 36) , and have a protein expression profile that differs from that of the parental strain (36) . Moreover, the LPS expression of Cap Ϫ mutants either is unknown or appears as a core structure without O-antigen side chains (17, 36, 42) . This difference in LPS expression between Cap Ϫ mutants and LVS ⌬capB, which expresses full-length ladder-like LPS molecules, likely accounts for the difference between these strains in their serum sensitivities. We found that O-antigen-deficient genetic mutants of LVS (LVS ⌬wbtDEF and LVS ⌬wzy) are highly serum sensitive ( Fig. 2B and our unpublished studies) . Previously, we developed an attenuated Listeria monocytogenes vaccine expressing a key immunoprotective F. tularensis protein, IglC, as a vaccine against tularemia (23) . This vaccine induced protection comparable to that of LVS at effective challenge doses of 1ϫ and 10ϫ the LD 50 of aerosolized F. tularensis SchuS4, but in a subsequent study involving a higher challenge dose, it was not as efficacious as LVS. This prompted us to embark on a different vaccine development strategy. To obtain a more potent vaccine against aerosolized type A F. tularensis, we hypothesized that we would need a vaccine that induced immune responses not just to one or two F. tularensis antigens but to a broad array of F. tularensis antigens, including nonprotein antigens such as LPS. This led us to employ an attenuated mutant of F. tularensis LVS, itself an attenuated version of the homologous but less virulent F. tularensis subsp. holarctica, as a vaccine and vector.
Using an attenuated version of the LVS vaccine as a vaccine vector has a tremendous safety advantage over other approaches to a tularemia vaccine because LVS has already been tested extensively in humans (18, 19, 29, 37) , and therefore, its safety profile, while nonideal, is well understood. It seems very likely that a vaccine like LVS ⌬capB that is more attenuated than LVS in both the highly susceptible mouse model and human macrophage-like THP-1 cells will have a safety profile that is better than that of LVS in humans. Determining whether this is so requires studies with humans.
Currently, four approaches to tularemia vaccines are being investigated: killed vaccines, subunit vaccines, live attenuated type A vaccines, and live attenuated non-type A vaccines. Of these, we believe the last approach, the one employed in this study, is the most promising because it provides the best combination of safety and efficacy, as discussed below.
Killed vaccines. Studies have shown that killed whole-cell vaccines do not afford high-level protection against type A F. tularensis in animal models (4, 10, 15, 29, 37, 38) .
Subunit vaccines. Subunit vaccines comprising an F. tularensis protein in an adjuvant formulation or F. tularensis LPS The differences in survival between the mice in the vaccinated groups and the mice in the sham-vaccinated group were evaluated by using a log-rank (Mantel-Cox) test (Prism 5.01). *** , P Ͻ 0.0001 versus Sham. a , 3 of 12 mice (25%) died after i.n. immunization with LVS; of the remaining 9 mice, 4 were studied for the data shown in A, and 5 were studied for the data shown in C.
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JIA (8, 13, 14, 40) . Also, capsule material prepared from virulent strain SchuS4 was unable to induce protective immunity in guinea pigs and mice against SchuS4 challenge (17) . Intraperitoneal immunization with an F. tularensis LVS outer membrane protein preparation protected 50% of mice challenged i.n. with type A SchuS4 (22) . Live attenuated type A vaccines. Live attenuated singledeletion F. tularensis type A strains carry a potential risk of reversion to virulence, and multiple deletions in type A strains have a tendency to reduce the immunogenicity of the vaccine. An F. tularensis SchuS4 mutant deficient in IglC was significantly attenuated but was unable to protect against type A F. tularensis challenge despite its ability to persist and disseminate to the liver and spleen of the host (9, 46 ). An FTT1103 deletion mutant of F. tularensis SchuS4 was found to be highly attenuated, but it provided protection against SchuS4 challenge only when administered i.n. at a dose of 10 8 CFU (9, 32) . A purified auxotroph of F. tularensis SchuS4 was found to give poor protection against i.n. challenge with the homologous parental organism and no better protection than an analogous purine auxotroph of the less virulent type B LVS strain (31) . An F. tularensis SchuS4 mutant with a deletion in clpB gave partial protection by the i.d. and oral routes (9, 46 ). An F. tularensis SchuS4 mutant deficient in FTT0918 was highly protective after i.d. administration (41) ; however, an additional deletion in capB gave reduced immunoprotection (9, 46) .
Live attenuated non-type A vaccines. Previously constructed live attenuated non-type A mutants have not afforded potent immunoprotection against virulent F. tularensis challenge. Oantigen-deficient mutants in F. tularensis subsp. tularensis, holarctica, and novicida were overattenuated in mice and therefore unable to induce protective immunity against type A strains (26, 33, 39, 44) . Similarly, our initial effort with Oantigen-deficient LVS strains (LVS ⌬wbtDEF and LVS ⌬wzy) failed to provide potent protection against respiratory challenge with F. tularensis. An F. tularensis subsp. novicida iglB mutant is significantly attenuated in mice; oral but not i.n. administration provided limited protection against F. tularensis SchuS4 challenge to mice (7) . An F. tularensis LVS deficient in iron superoxide dismutase was found to be protective against F. tularensis SchuS4 challenge following i.n. immunization with 5 ϫ 10 3 CFU of this mutant (3). However, i.n. inoculation of 1 ϫ 10 4 CFU of this mutant caused 17% and 40% deaths in C57BL/6 and BALB/c mice, respectively, indicating an underattenuation of this strain (2) . In contrast to these vaccines, the LVS ⌬capB vaccine is neither overattenuated nor underattenuated. At the same time, because LVS ⌬capB contains multiple defined noncontiguous deletions, including most of the FTT0918, pilA, and capB genes, there is extremely little likelihood of reversion to virulence to the wild-type F. tularensis subsp. holarctica strain, a less virulent subspecies than F. tularensis subsp. tularensis to begin with.
Note that LVS ⌬capB shares some common genetic features with the SchuS4 ⌬FTT0918 ⌬capB strain (9) . FTT0918 has been shown to be essential for the virulence of strain SchuS4 (46) . In LVS, only the C terminus of FTT0918 remains, which forms a fusion protein with the N terminus of FTT0919. The reintroduction of FTT0918 in cis partially restores virulence to LVS, and the reintroduction of both FTT0918 and pilA fully restores the virulence of LVS (35) to that of wild-type F. tularensis subsp. holarctica. Given that three major deletions (most of the FTT0918, pilA, and capB genes) were necessary to reduce the virulence of the parent of LVS to a nontoxic level and that LVS contains additional gene deletions, it is perhaps not surprising that a SchuS4 mutant with only a double deletion in FTT0918 and capB remains partially virulent in BALB/c mice and fully virulent in C3H/HeN mice (9) .
In summary, LVS ⌬capB, while Ͼ10,000-fold-less virulent than LVS by the respiratory route, induces potent protective immunity against lethal F. tularensis respiratory challenge comparable to that of LVS after i.n. administration. By the i.d. route of administration, LVS ⌬capB offers significant protection although less than that of LVS against F. tularensis SchuS4 aerosol challenge. Balancing safety and efficacy, LVS ⌬capB, an antibiotic-marker-free vaccine that is immunoprotective in mice at doses that are completely nontoxic, already has the potential to offer a reasonable alternative to the LVS vaccine.
In future studies, we shall evaluate the efficacy of recombinant versions of LVS ⌬capB overexpressing F. tularensis immunoprotective proteins. The concept of a vaccine vector overexpressing native immunogenic proteins, as opposed to expressing foreign antigens, is a new paradigm in vaccinology pioneered in this laboratory; the value of the concept was demonstrated in the development of novel tuberculosis vaccines (20, 21) . Preliminary studies indicate that the expression of native F. tularensis proteins in LVS ⌬capB will significantly enhance its efficacy.
